系统性红斑狼疮B细胞靶向治疗应答分层生物标志物的识别:一项随机对照试验的探索性分析
该研究为BEAT-LUPUS随机对照试验的探索性分析,纳入52例系统性红斑狼疮患者,其中44例有第52周临床数据,比较利妥昔单抗后贝利尤单抗与利妥昔单抗后安慰剂的疗效。基线血清IgA2抗双链DNA抗体浓度升高者中,两组主要临床应答率差异为48%(95%CI 10至70),且仅贝利尤单抗组应答者该抗体浓度较基线显著下降。循环IgA2浆母细胞和滤泡辅助性T细胞数量可预测应答,基线血清白介素-6浓度高者主要临床应答可能性较低。
要点
- 基线血清IgA2抗dsDNA抗体浓度升高者中,贝利尤单抗组与安慰剂组主要临床应答差异为48%(95%CI 10至70)。
- 仅贝利尤单抗组主要临床应答者血清IgA2抗dsDNA抗体浓度较基线显著下降。
- 循环IgA2浆母细胞和滤泡辅助性T细胞数量可预测应答,且仅在贝利尤单抗组应答者中减少。
核心结论
- 该探索性研究揭示了与肾脏和黏膜皮肤受累及B细胞靶向治疗应答相关的不同分子网络,若经证实,可能指导该异质性疾病先进治疗的精准靶向。
研究设计与样本
- BEAT-LUPUS随机对照试验的探索性分析,2017年2月2日至2019年3月28日招募52例SLE患者,44例提供第52周临床数据并纳入分析。
- 试验比较利妥昔单抗联合贝利尤单抗与利妥昔单抗联合安慰剂,采用机器学习和常规统计方法分析主要临床应答相关的实验室和临床生物标志物。
- 贝利尤单抗组21例(48%),平均年龄39.5岁(SD 12.1),女性17例(81%)、男性4例(19%),白人13例(62%)。
- 安慰剂组23例(52%),平均年龄42.1岁(SD 10.5),女性21例(91%)、男性2例(9%),白人16例(70%)。
主要发现
- 贝利尤单抗组21例中10例(48%)与安慰剂组23例中8例(35%)在第52周达到主要临床应答,组间差异13%(95%CI -15至38)。
- 基线血清IgA2抗dsDNA抗体浓度升高的患者中,主要临床应答组间差异为48%(95%CI 10至70)。
- 在达到主要临床应答者中,仅贝利尤单抗组血清IgA2抗dsDNA抗体浓度较基线显著下降。
- 循环IgA2浆母细胞(而非总浆母细胞)和滤泡辅助性T细胞数量可预测临床应答,且仅在利妥昔单抗后贝利尤单抗应答者中减少。
- 基线血清白介素-6浓度高的患者主要临床应答可能性较低,与治疗无关。
关键数值与推荐
- 基线血清IgA2抗dsDNA抗体浓度与利妥昔单抗后贝利尤单抗临床应答存在预测性关联,该亚组主要临床应答组间差异48%(95%CI 10至70)。
- 血清IgA2抗dsDNA抗体浓度与活动性肾脏病相关,血清IgA1抗dsDNA抗体和IFN-α浓度与黏膜皮肤疾病活动度相关但不预测B细胞靶向治疗应答。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为探索性分析。
- 原文结论指出相关发现若经证实,可能指导精准靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic lupus erythematosus (SLE) is a complex autoimmune disease associated with widespread immune dysregulation and diverse clinical features. Immune abnormalities might be differentially associated with specific organ involvement or response to targeted therapies. We aimed to identify biomarkers of response to belimumab after rituximab to facilitate a personalised approach to therapy. METHODS: In this exploratory analysis of a randomised controlled trial (BEAT-LUPUS), we investigated immune profiles of patients with SLE recruited to the 52-week clinical trial, which tested the combination of rituximab plus belimumab versus rituximab plus placebo. We used machine learning and conventional statistics to investigate relevant laboratory and clinical biomarkers associated with major clinical response. BEAT LUPUS is registered at ISRCTN, 47873003, and is now complete. FINDINGS: Between Feb 2, 2017, and March 28, 2019, 52 patients were recruited to BEAT-LUPUS, of whom 44 provided clinical data at week 52 and were included in this analysis. 21 (48%) of 44 participants were in the belimumab group (mean age 39·5 years [SD 12·1]; 17 [81%] were female, four [19%] were male, 13 [62%] were White) and 23 (52%) were in the placebo group (mean age 42·1 years [SD 10·5]; 21 [91%] were female, two [9%] were male, 16 [70%] were White). Ten (48%) of 21 participants who received belimumab after rituximab and eight (35%) of 23 who received placebo after rituximab had a major clinical response at 52 weeks (between-group difference of 13% [95% CI -15 to 38]). We found a predictive association between baseline serum IgA2 anti-double stranded DNA (dsDNA) antibody concentrations and clinical response to belimumab after rituximab, with a between-group difference in major clinical response of 48% (95% CI 10 to 70) in patients with elevated baseline serum IgA2 anti-dsDNA antibody concentrations. Moreover, among those who had a major clinical response, serum IgA2 anti-dsDNA antibody concentrations significantly decreased from baseline only in the belimumab group. Increased circulating IgA2 (but not total) plasmablast numbers, and T follicular helper cell numbers predicted clinical response and were both reduced only in patients who responded to belimumab after rituximab. Serum IgA2 anti-dsDNA antibody concentrations were also associated with active renal disease, whereas serum IgA1 anti-dsDNA antibody and IFN-α concentrations were associated with mucocutaneous disease activity but did not predict response to B-cell targeted therapy. Patients with a high baseline serum interleukin-6 concentration were less likely to have a major clinical response, irrespective of therapy. INTERPRETATION: This exploratory study revealed the presence of distinct molecular networks associated with renal and mucocutaneous involvement, and response to B-cell-targeted therapies, which, if confirmed, could guide precision targeting of advanced therapies for this heterogenous disease. FUNDING: Versus Arthritis, UCLH Biomedical Research Centre, LUPUS UK, and GSK.
引用
- Shipa M, Santos LR, Nguyen DX, et al. Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial. Lancet Rheumatol. 2022. PMID: 36756239. doi:10.1016/S2665-9913(22)00332-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。